Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ0IOF)

• Drug Name: ICI-169369 Drug Info
• Synonyms: 2-Detpq; Ici 169369; 2-((2-(dimethylamino)ethyl)thio)-3-phenylquinoline; 85273-95-6; Ici-169,369; UNII-4CT4CS5BA7; ICI-169369; 4CT4CS5BA7; N,N-dimethyl-2-(3-phenylquinolin-2-yl)sulfanylethanamine; Ethanamine, N,N-dimethyl-2-((3-phenyl-2-quinolinyl)thio)-; Ethanamine, N,N-dimethyl-2-[(3-phenyl-2-quinolinyl)thio]-; AC1L3UA4; GTPL273; AC1Q7E25; SCHEMBL2640021; CHEMBL1191534; CTK2I4265; BDBM84945; DTXSID40234468; 85273-96-7 (hydrochloride); n,n-dimethyl-2-[(3-phenylquinolin-2-yl)sulfanyl]ethanamine; ZINC5140456; PDSP2_001405

Indication

Disease Entry	ICD 11	Status	REF
Anxiety disorder	6B00-6B0Z	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 122265
  CAS Number: CAS 85273-95-6
  TTD Drug ID: DMQ0IOF

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[4]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[5]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[6]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[7]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[8]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[9]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[10]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[11]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[12]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[13]

Drug(s) Targeting 5-HT 2C receptor (HTR2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[4]
Lorcaserin	DMG6OYJ	Obesity	5B81	Approved	[14]
Tramadol	DMRQD04	Osteoarthritis	FA00-FA05	Approved	[15]
Mirtazapine	DML53ZJ	Depression	6A70-6A7Z	Approved	[16]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[17]
Methysergide	DM1EF73	Migraine	8A80	Approved	[18]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[19]
M100907	DM7ZFBA	Sleep-wake disorder	7A00-7B2Z	Phase 3	[20]
SR46349B	DM1ODMR	Primary insomnia	7A00	Phase 3	[21]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[22]

Drug(s) Affected By 5-hydroxytryptamine receptor 7 (HTR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[23]
Cyproheptadine	DM92AH3	Allergic rhinitis	CA08.0	Approved	[3]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[3]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[25]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[26]
PD-0325901	DM27D4J	Breast cancer	2C60-2C65	Phase 2	[27]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[28]
SL65.0472	DMU5RKC	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[29]
SB-269970	DM8WTGA	Sleep-wake disorder	7A00-7B2Z	Terminated	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Modulator	[2]
5-HT 2C receptor (HTR2C)	TTWJBZ5	5HT2C_HUMAN	Modulator	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5-hydroxytryptamine receptor 7 (HTR7)	OT44DEWB	5HT7R_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 273).
• [2] Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects.Drugs Today (Barc).2010 Mar;46(3):183-93.
• [3] Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions. Psychopharmacology (Berl). 2010 Dec;212(4):687-97. doi: 10.1007/s00213-010-2001-x. Epub 2010 Sep 9.
• [4] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [5] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [6] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [7] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [8] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [9] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [11] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [12] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [13] Clinical pipeline report, company report or official report of Lundbeck.
• [14] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [15] The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
• [16] Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
• [17] Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
• [18] Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
• [19] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [20] Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
• [21] SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
• [22] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
• [23] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [24] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [25] Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics. 2006 Apr 3;7:68. doi: 10.1186/1471-2164-7-68.
• [26] Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007 Sep;36(3):329-35. doi: 10.1002/mus.20871.
• [27] PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014 Oct 9;514(7521):247-51.
• [28] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [29] Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.